At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma
In Brief
A Phase 2 clinical trial evaluating Ipilimumab, Nivolumab, and 1 other intervention for Metastatic Malignant Neoplasm in the Liver and 2 related conditions. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
Study Details
Timeline
Interventions
Given IV
Given IV
Undergo immunoembolization